Last reviewed · How we verify
Late-infantile neuronal ceroid lipofuscinosis
Approved treatments
- Rhttp1 · BioMarin
Cerliponase alfa works by inhibiting the breakdown of a protein called tripeptidyl peptidase, which is deficient in patients with late-infantile neuronal ceroid lipofuscinosis.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Late-infantile neuronal ceroid lipofuscinosis patent landscape — cliff calendar, originator estates, attackable patents
- Late-infantile neuronal ceroid lipofuscinosis treatment landscape brief
- Late-infantile neuronal ceroid lipofuscinosis treatment updates RSS
Frequently asked questions about Late-infantile neuronal ceroid lipofuscinosis
What drugs treat Late-infantile neuronal ceroid lipofuscinosis?
Tracked treatments include Rhttp1.
What is the treatment for Late-infantile neuronal ceroid lipofuscinosis?
Standard treatment for Late-infantile neuronal ceroid lipofuscinosis includes Rhttp1. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Late-infantile neuronal ceroid lipofuscinosis patent cliff · Late-infantile neuronal ceroid lipofuscinosis CI report
- Treatment: Rhttp1 · BioMarin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing